P1119 EARLY VIRAL KINETICS DO NOT PREDICT TREATMENT OUTCOME WITH SOFOSBUVIR + RIBAVIRIN FOR 12 OR 24 WEEKS IN HCV GENOTYPE 2/3 PATIENTS IN THE VALENCE TRIAL

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Hepatology

• Publication date

  2014-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0168-8278(14)61279-4
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis

  2019cites this paper
• Diagnostics in hepatitis C: The end of response-guided therapy?

  2016cites this paper
• Resurrection of response-guided therapy for sofosbuvir combination therapies.

  2016cites this paper
• HCV-RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin.

  2016cites this paper
• Hepatitis C treatment: an incipient therapeutic revolution.

  2014cites this paper
• Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era.

  2014cites this paper
• Sofosbuvir: A Review of its Use in Patients with Chronic Hepatitis C

  2014cites this paper